Promethazine

Introduction Overview

Generic Name

promethazine

Brand Name

Phenergan

Dosage Form

Oral tablets, oral syrup, rectal suppositories, injectable formulations

Drug Class

Antihistamines, Phenothiazine antiemetics

Pharmacokinetics

Absorption:
Promethazine is well absorbed from the gastrointestinal tract following oral administration, with peak plasma concentrations typically achieved within 2 to 3 hours. The bioavailability may vary due to first-pass hepatic metabolism. When administered via other routes such as rectal or intramuscular injection, absorption kinetics are altered; rectal administration provides a slower onset with more prolonged effects, whereas intramuscular injection results in rapid absorption and onset of action. Factors such as gastric pH, presence of food, and gastrointestinal motility can influence its absorption. Clinical implications include ensuring dosing timing in relation to meals when considering onset of effect.

Distribution:
Promethazine is extensively distributed throughout the body and is highly lipophilic, allowing penetration across the blood-brain barrier. It demonstrates a high volume of distribution, accumulating in tissues such as the liver, lungs, and kidneys, and especially in the central nervous system (CNS), accounting for its sedative effects. It is approximately 76% to 93% bound to plasma proteins, predominantly albumin. This protein binding can be influenced in hypoalbuminemic states, potentially altering free drug concentrations. Its CNS penetration underlies both therapeutic effects and CNS-related adverse events.

Metabolism:
Promethazine undergoes extensive hepatic metabolism primarily via cytochrome P450 enzymes, notably CYP2D6 and CYP1A2. Its primary metabolic pathways include N-demethylation and aromatic ring hydroxylation leading to inactive metabolites. The metabolic rate can be affected by genetic polymorphisms in CYP enzymes, as well as concurrent use of enzyme inducers or inhibitors, which might increase toxicity or reduce efficacy. Hepatic impairment can lead to decreased metabolism and accumulation of promethazine, necessitating dose adjustments in liver disease patients.

Elimination:
The elimination half-life of promethazine ranges between 10 to 19 hours, exhibiting considerable interindividual variability. It is mainly excreted via the urine as metabolites, with less than 1% excreted unchanged. Renal impairment may alter clearance of metabolites, although significant accumulation of promethazine itself is uncommon. Biliary excretion also contributes to elimination. Clinically, dosing adjustments may be necessary in severe renal impairment, and the prolonged half-life warrants caution in elderly patients who are more susceptible to accumulation and adverse effects.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 12.5 mg, 25 mg, 50 mg
- Oral syrup: typically 6.25 mg per 5 mL
- Rectal suppositories: 12.5 mg, 25 mg
- Injectable: 25 mg/mL in 1 mL, 2 mL vials for intramuscular or intravenous administration

Dosages for Adults and Adolescents:
For allergies and motion sickness, typical oral adult dosing ranges from 12.5 mg to 25 mg every 4 to 6 hours, not exceeding 100 mg in 24 hours. For nausea and vomiting, doses may be similar but administered before symptoms or surgery, sometimes as a single dose. Intramuscular or intravenous injection dosing in adults is commonly 12.5 to 25 mg every 4 to 6 hours as necessary. For sedation, single doses of 25 mg are often used. Rectal suppositories are dosed similarly for patients unable to take oral forms.

Specific Patient Populations:
Children over 2 years should be dosed cautiously, typically using weight-based dosing of 0.25 to 0.5 mg/kg every 4 to 6 hours, avoiding use under 2 years due to respiratory depression risk. In elderly patients, lower doses are recommended due to increased sensitivity and decreased clearance. Hepatic or renal impairment requires individualized dosing with careful monitoring. During pregnancy, use only if benefits outweigh risks, and breastfeeding is generally not advised during therapy.

Mechanism Of Action

Promethazine is a phenothiazine derivative that primarily acts as a potent antagonist at histamine H1 receptors. By blocking these receptors, it prevents the action of endogenous histamine, thereby mitigating symptoms associated with allergic reactions such as itching, edema, and vasodilatation. The antagonism at peripheral H1 receptors underpins its efficacy in allergic conditions.

Beyond antihistaminic properties, promethazine exerts significant anticholinergic effects by competitively inhibiting muscarinic receptors. This activity contributes to its antiemetic properties by suppressing the vestibular apparatus of the inner ear and chemoreceptor trigger zone, thereby preventing nausea and vomiting, especially from motion sickness or postoperative causes.

Promethazine also has sedative and hypnotic effects mediated by its interaction with central H1 receptors within the CNS and its ability to depress the reticular activating system. Additionally, its chemical structure closely resembles that of neuroleptic phenothiazines, conferring weak dopaminergic antagonism, although this is less pronounced than typical antipsychotics. This dopamine receptor blockade partly contributes to extrapyramidal side effects observed in some patients.

Clinical implications of these multiple mechanisms allow promethazine to serve multi-purpose roles as an antihistamine, antiemetic, and sedative. Compared to other antihistamines, it is more sedating and has broader receptor activity. Clinical trials have demonstrated its efficacy in preventing perioperative nausea and as an adjunct in allergy management. Ongoing research explores its receptor-binding affinities and potential CNS effects, guiding optimized therapeutic use.

Pharmacological Actions

Antihistaminic activity via H1 receptor antagonism reducing allergy symptoms.
Antiemetic effect by blocking vestibular and chemoreceptor trigger zones.
Sedative and hypnotic properties induced through central H1 receptor blockade.
Anticholinergic effects reducing vestibular stimulation and secretions.
Weak dopamine receptor antagonism linked to rare extrapyramidal symptoms.
Inhibition of the vomiting center in the medulla oblongata.
Reduction of histamine-induced vasodilatation and capillary permeability.
Central nervous system depressant effect contributing to anxiolysis.

Therapeutic Or Clinical Uses

Management of allergic conditions including urticaria, rhinitis, and pruritus.
Prevention and treatment of motion sickness and associated nausea.
Treatment of nausea and vomiting related to surgery or medication side effects.
Sedation and preoperative anesthesia adjunct to reduce patient anxiety.
Relief of allergic conjunctivitis and dermatologic allergic manifestations.
Adjunctive therapy in respiratory allergies with symptomatic relief.
Control of allergic reactions to blood transfusion or insect bites.
Used off-label as a nighttime sleep aid under medical supervision.

Side Or Adverse Effects

Drowsiness and sedation, potentially impairing driving and cognitive function.
Dizziness and possible orthostatic hypotension leading to falls.
Dry mouth due to anticholinergic effects.
Blurred or double vision from pupillary disturbances.
Extrapyramidal symptoms including dystonia, akathisia, or tardive dyskinesia.
Respiratory depression, severe in young children, especially under 2 years.
Confusion, hallucinations, and agitation mainly in elderly or sensitive individuals.
Photosensitivity reactions with increased susceptibility to sunburn.
Gastrointestinal disturbances such as nausea and constipation.
Allergic reactions including rash, urticaria, and anaphylaxis in rare cases.
Hypotension and potential cardiovascular effects like arrhythmias.
Jaundice and liver enzyme abnormalities reported rarely.
Potential for anticholinergic toxicity at high doses or overdose.
Possibility of seizures in predisposed individuals.
Prolonged QT interval and associated risk of cardiac arrhythmias.

Precautions

Avoid use in children younger than 2 years due to risk of fatal respiratory depression.
Use with caution in patients with respiratory diseases such as asthma or COPD.
Monitor closely if history of seizures or CNS depression is present.
Avoid concurrent use with alcohol or CNS depressants to prevent enhanced sedation.
Use carefully in patients with cardiovascular disease or hypotension tendencies.
Consider dose adjustment or alternative therapy in hepatic or renal impairment.
Avoid abrupt withdrawal after prolonged use to prevent rebound symptoms.
Take care with patients having glaucoma, especially narrow-angle glaucoma.
Monitor for extrapyramidal symptoms in long-term or high-dose therapy.
Assess for potential drug interactions prior to initiation, especially with sedatives and anticholinergics.
Use caution in elderly due to increased sensitivity and risk of confusion or falls.
Pregnancy use only if clearly needed; discuss potential risks and benefits.
Advise patients to avoid sun exposure or use sun protection due to photosensitivity.
Inform patients about impairment of mental alertness and operating machinery.
Monitor urinary retention in patients with prostatic hypertrophy.

Warnings

Risk of severe respiratory depression and death in children under 2 years; contraindicated.
Potential for serious extrapyramidal and tardive dyskinesia side effects.
May cause severe CNS depression leading to coma in overdose situations.
Can impair mental and motor skills; avoid driving or hazardous activities.
Photosensitivity reactions necessitate sun avoidance and protective measures.
Risk of neuroleptic malignant syndrome, a rare but life-threatening condition.
Potential for severe allergic reactions including anaphylaxis.
Avoid use in patients with known hypersensitivity to promethazine or phenothiazines.
May exacerbate symptoms of respiratory depression in COPD or asthma patients.
Use caution with concomitant CNS depressants due to risk of additive sedative effects.
Pregnancy category C — potential fetal risk, use only if benefits justify.
Not recommended during breastfeeding due to unknown excretion in milk.
Requires careful monitoring in patients with cardiovascular disease due to arrhythmia risk.
Warn patients about dizziness and orthostatic hypotension to prevent falls.
Has been associated with fatal respiratory depression when administered by intravenous route improperly.

Contraindication

Children younger than 2 years due to risk of severe respiratory depression.
Known hypersensitivity to promethazine or other phenothiazine derivatives.
Patients with severe respiratory depression or comatose states.
Severe CNS depression from any cause.
Use of large doses of CNS depressants concomitantly due to potentiation of CNS depression.
Active central nervous system depression or medication-induced CNS depression.
Narrow-angle glaucoma due to anticholinergic effects worsening the condition.
Bone marrow suppression or hematologic diseases due to risk of blood dyscrasias.
Patients with severe hepatic impairment without dose adjustment and monitoring.
Known sensitivity or allergy to sulfite preservatives contained in some injectable forms.
Use with caution or avoidance in patients with pyloric or intestinal obstruction.
Those with severe cardiovascular disease experiencing arrhythmias or hypotension.
Use contraindicated if prior serious adverse reaction to phenothiazines occurred.
Patients receiving monoamine oxidase inhibitors concurrently or within 14 days.
Breastfeeding mothers due to unknown effects on infant safety.

Drug Interactions

Additive CNS depression when combined with sedatives, narcotics, anxiolytics, or alcohol.
Enhanced anticholinergic effects with antihistamines, tricyclic antidepressants, and antipsychotics.
Potential potentiation of respiratory depression with other respiratory depressants.
Interaction with lithium leading to increased neurotoxicity risk.
Antagonism or synergism with dopamine agonists or antagonists affecting CNS balance.
Possible alteration of warfarin anticoagulant activity requiring close monitoring.
Concomitant use with monoamine oxidase inhibitors (MAOIs) may precipitate hypertensive crisis.
Interactions with anticholinergic drugs such as atropine, scopolamine, and belladonna derivatives.
CYP450 enzyme inhibitors or inducers can affect promethazine metabolism, altering effectiveness or toxicity.
Increased risk of QT prolongation with other medications that affect cardiac conduction.
Bladder or urinary retention drugs may exacerbate urinary side effects when used together.
Bronchodilators like ipratropium or tiotropium combined with promethazine may amplify anticholinergic burden.
Drugs that lower seizure threshold may enhance seizure risk when combined with promethazine.
Concurrent use with blood pressure medications like propranolol may produce additive hypotensive effects.
Interactions with gastrointestinal motility agents or stomach ulcer medications require clinical monitoring.

Preparations Of The Drug

Phenergan tablets: available in 12.5 mg, 25 mg, and 50 mg oral tablet formulations.
Phenergan syrup: oral solution typically dosed at 6.25 mg per 5 mL for pediatric use.
Phenergan injectable: intramuscular and intravenous solutions at 25 mg/mL concentration for acute management.
Phenergan suppositories: rectal formulations in 12.5 mg and 25 mg strengths for patients unable to take oral medications.
Combination products including promethazine with codeine or dextromethorphan for cough and cold management (available under various brand names).
Injectable preparations should be administered carefully due to risk of tissue injury and extravasation.
Oral disintegrating tablets and eliminations in compounded formulations for specific patient populations or dosing requirements.
Preservative-free injectable formulations available to mitigate sulfite hypersensitivity reactions.
Liquid preparations may include flavoring agents to enhance pediatric compliance.
Packaging includes dosing syringes and measuring cups for precise liquid dosing.
Typically supplied in blister packs, bottles, ampules, or vials depending on formulation.
Storage requirements at room temperature protected from moisture, light, and heat to preserve potency.
Available under various international brand names including Phenergan, Promethegan, and Phenadoz.
Patient counseling emphasizes avoiding changing formulations without medical advice.
Injection formulations are intended for healthcare provider administration and should be used with caution.